Literature DB >> 7538132

An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors.

J D Wright1, C W Reuter, M J Weber.   

Abstract

Although signaling by the epidermal growth factor (EGF) receptor is thought to be dependent on receptor tyrosine kinase activity, it is clear that mitogen-activated protein (MAP) kinase can be activated by receptors lacking kinase activity. Since analysis of the signaling pathways used by kinase-defective receptors could reveal otherwise masked capabilities, we examined in detail the tyrosine phosphorylations and enzymes of the MAP kinase pathway induced by kinase-defective EGF receptors. Following EGF stimulation of B82L cells expressing a kinase-defective EGF receptor mutant (K721M), we found that ERK2 and ERK1 MAP kinases, as well as MEK1 and MEK2 were all activated, and SHC became prominently tyrosine-phosphorylated. By contrast, kinase-defective receptors failed to induce detectable phosphorylations of GAP (GTPase-activating protein), p62, JAK1, or p91STAT1, all of which were robustly phosphorylated by wild-type receptors. These data demonstrate that kinase-defective receptors induce several protein tyrosine phosphorylations, but that these represent only a subset of those seen with wild-type receptors. This suggests that kinase-defective receptors activate a heterologous tyrosine kinase with a specificity different from the EGF receptor. We found that kinase-defective receptors induced ErbB2/c-Neu enzymatic activation and ErbB2/c-Neu binding to SHC at a level even greater than that induced by wild-type receptors. Thus, heterodimerization with and activation of endogenous ErbB2/c-Neu is a possible mechanism by which kinase-defective receptors stimulate the MAP kinase pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538132     DOI: 10.1074/jbc.270.20.12085

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

2.  Phenolic antioxidants trolox and caffeic acid modulate the oxidized LDL-induced EGF-receptor activation.

Authors:  N Vacaresse; O Vieira; F Robbesyn; G Jürgens; R Salvayre; A Negre-Salvayre
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  erbB2 is required for G protein-coupled receptor signaling in the heart.

Authors:  Alejandra Negro; Bhawanjit K Brar; Yusu Gu; Kirk L Peterson; Wylie Vale; Kuo-Fen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

4.  Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents.

Authors:  A Knebel; H J Rahmsdorf; A Ullrich; P Herrlich
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor.

Authors:  D W Leaman; S Pisharody; T W Flickinger; M A Commane; J Schlessinger; I M Kerr; D E Levy; G R Stark
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

6.  Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.

Authors:  K M Ferguson; P J Darling; M J Mohan; T L Macatee; M A Lemmon
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 7.  The biology of human epidermal growth factor receptor 2.

Authors:  S Sundaresan; E Penuel; M X Sliwkowski
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

8.  Epidermal growth factor receptors control competence to interpret leukemia inhibitory factor as an astrocyte inducer in developing cortex.

Authors:  Jane Viti; Angela Feathers; Jennifer Phillips; Laura Lillien
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

9.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

10.  Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation.

Authors:  F Walker; A Kato; L J Gonez; M L Hibbs; N Pouliot; A Levitzki; A W Burgess
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.